Calgary Mind & Wellness Clinic on Facebook

Phone: 780-978-9010 

rTMS After Concussion and Mild Traumatic Brain Injury: Evidence Review

by | Sep 4, 2026 | EXOMIND & rTMS Research, Neurofeedback & Brain Health

EXOMIND & rTMS Research Library

Researchers have studied rTMS for persistent symptoms after concussion and mild traumatic brain injury, including headache, depression and cognitive complaints. The evidence remains early.

Why this finding matters

Persistent post-concussion symptoms can disrupt work, mood, sleep and cognitive confidence. Early studies justify continued investigation, but they do not establish rTMS as a standard concussion treatment.

Research Spotlight

Early clinical evidence

  • Systematic review evidence
  • Small heterogeneous trials
  • Post-concussion symptoms studied
  • Not an established indication

What the evidence suggests

A systematic review identified clinical trials examining rTMS after concussion or mild traumatic brain injury. Some studies reported improvements in selected symptoms, but protocols and outcomes varied and the evidence base was small.

What this could mean for you

Persistent symptoms require careful assessment for neurological, psychological, sleep, pain and functional contributors. rTMS may be discussed only within a broader rehabilitation plan when clinically appropriate.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Start with the right clinical question

We can review the symptoms and goals to determine whether assessment, rehabilitation, psychological care or an emerging neuromodulation option is the most appropriate discussion.

Book a Consultation   Explore the related Calgary service

Study citation

Mollica et al. Transcranial magnetic stimulation for the treatment of symptoms following concussion/mild traumatic brain injury. PMID: 33184973.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

Neurofeedback for Anxiety and Stress Regulation: Evidence Review

by | Sep 4, 2026 | Anxiety Treatment, Neurofeedback & Brain Health

Neurofeedback & qEEG Research Library

Biofeedback and neurofeedback have been studied for anxiety and physiological regulation. The evidence suggests potential benefit, but it remains difficult to separate specific neurofeedback effects from attention, expectation and other treatment factors.

Why this finding matters

Anxiety is influenced by physiology, attention, expectation and coping patterns. Biofeedback approaches may help some people practise regulation, but active-control findings show why a complete plan matters more than relying on technology alone.

Research Spotlight

Promising, with nonspecific effects

  • Biofeedback beats wait-list controls
  • Not consistently superior to active care
  • EEG evidence remains developing
  • Clinical context matters

What the evidence suggests

A meta-analytic review found broadly defined biofeedback superior to wait-list conditions, but not superior to active treatment or countertherapeutic physiological training. Reviews of EEG neurofeedback describe developing evidence rather than a settled first-line indication.

What this could mean for you

Neurofeedback may be discussed as an adjunct for arousal and self-regulation when it fits the clinical formulation. Evidence-based psychotherapy—particularly cognitive behavioural and exposure-based approaches—remains central for anxiety disorders.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Explore a regulation-focused plan

We can discuss symptoms, treatment history and measurable goals before determining whether neurofeedback should be considered.

Book a Consultation   Explore the related Calgary service

Related Calgary service: Neurofeedback Calgary

Study citation

Tolin et al. Biofeedback and neurofeedback for anxiety disorders: a quantitative and qualitative systematic review. PMID: 32002934.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

Neurofeedback for Sleep and Insomnia: Why the Evidence Is Mixed

by | Sep 4, 2026 | Mental Health & Wellness, Neurofeedback & Brain Health

Neurofeedback & qEEG Research Library

Research on neurofeedback for insomnia is mixed. Some studies report improved subjective sleep, while controlled studies and objective sleep measures do not consistently show benefits beyond placebo or other care.

Why this finding matters

Feeling that sleep has improved is important, but objective sleep measures have not consistently confirmed a specific neurofeedback effect. This distinction helps people avoid paying for a service on the basis of claims the research cannot yet support.

Research Spotlight

Subjective and objective outcomes differ

  • 12-study review
  • Subjective sleep often improved
  • Objective findings contradictory
  • Placebo effects possible

What the evidence suggests

A review of 12 studies reported subjective improvement across included neurofeedback studies, but objective findings were contradictory. A later meta-analysis found no additional benefit from surface neurofeedback for self-perceived sleep compared with control conditions.

What this could mean for you

Sleep complaints deserve assessment for behavioural, psychological, medical and circadian contributors. Neurofeedback may be considered selectively, but cognitive behavioural therapy for insomnia and medical evaluation remain important established pathways.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Choose the pathway that fits the sleep problem

A consultation can help identify whether regulation training, psychological care or medical sleep assessment is the more appropriate next step.

Book a Consultation   Explore the related Calgary service

Related Calgary service: Neurofeedback Calgary

Study citation

Recio-Rodriguez et al. Neurofeedback to enhance sleep quality and insomnia: systematic review and meta-analysis. PMID: 39568666.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

Neurofeedback for Depression: What a 22-Study Meta-Analysis Found

by | Sep 4, 2026 | Depression Treatment, Neurofeedback & Brain Health

Neurofeedback & qEEG Research Library

A 2024 meta-analysis reported moderate pooled effects of neurofeedback on depressive symptoms, neurophysiological outcomes and neuropsychological functioning.

Why this finding matters

The review found moderate pooled effects across depressive symptoms, brain-based measures and cognitive functioning. That pattern is encouraging because depression can affect mood, energy, concentration and daily performance—not only one symptom score.

Research Spotlight

22 studies synthesized

  • Depression symptoms g −0.600
  • Neurophysiology g −0.726
  • Neuropsychological function g −0.418
  • Methods varied

What the evidence suggests

Across 22 studies, the pooled effect size for depression symptoms was Hedges g −0.600. The reported effects were −0.726 for neurophysiological outcomes and −0.418 for neuropsychological functioning.

What this could mean for you

The findings support considering neurofeedback as a complementary intervention for selected clients with depression, particularly within an integrated plan that may include psychotherapy, medication review and lifestyle supports.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Could neurofeedback complement your care?

We can review your goals, current treatment and the limits of the evidence before deciding whether a structured neurofeedback plan is reasonable.

Book a Consultation   Explore the related Calgary service

Related Calgary service: Neurofeedback Calgary

Study citation

Xia et al. Uncovering the power of neurofeedback: a meta-analysis of its effectiveness in treating major depressive disorders. PMID: 38889442 · DOI: 10.1093/cercor/bhae252.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.

Neurofeedback for PTSD: Research Findings and Important Limitations

by | Sep 4, 2026 | Neurofeedback & Brain Health, Trauma Treatment

Neurofeedback & qEEG Research Library

A systematic review and meta-analysis found promising reductions in PTSD symptoms following neurofeedback, while emphasizing that the trials were small and varied in population, protocol and quality.

Why this finding matters

The pooled results are encouraging for people experiencing trauma-related dysregulation, but they come from only seven varied trials. The most persuasive conclusion is that neurofeedback deserves thoughtful consideration as an adjunct—not that it replaces trauma-focused care.

Research Spotlight

7 randomized trials reviewed

  • Pooled SMD −1.76
  • 79.3% pooled remission in NFB groups
  • 24.4% in controls
  • Small heterogeneous studies

What the evidence suggests

Seven randomized controlled trials were included. The pooled standardized mean difference for PTSD symptoms was −1.76, and the reported mean remission rate was 79.3% in neurofeedback groups compared with 24.4% in control groups.

What this could mean for you

The results support further clinical discussion of neurofeedback as a possible adjunct for trauma-related dysregulation. Trauma-focused psychotherapy remains central, and treatment planning should consider safety, stability and readiness.

A careful, individualized next step

Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.

Explore whether neurofeedback is clinically appropriate

We review stability, treatment history, goals and readiness before recommending any package or protocol.

Book a Consultation   Explore the related Calgary service

Related Calgary service: Neurofeedback Calgary

Study citation

Askovic et al. Neurofeedback for post-traumatic stress disorder: systematic review and meta-analysis of clinical and neurophysiological outcomes. PMID: 37732560.

View the original record on PubMed

Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.